TargetBeta
EDNRB
endothelin receptor type B · also ETB, HSCR2, HSCR · Endothelin receptors
2 programs in company-led studies act on EDNRB, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Bosentanrule | Johnson & Johnson | antagonist | phase 4 | 370 running | EDNRA | ChEMBL |
| aprocitentanrule | Idorsia Pharmaceuticals | antagonist | phase 3 | 141 running | EDNRA | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- digital ulcers, 1 program
- Essential Hypertension, 1 program
- Hypertension, 1 program
- Hypertension, Pulmonary, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Liver Diseases, 1 program
- Pulmonary Arterial Hypertension, 1 program
- Renal Insufficiency, 1 program
- Scleroderma, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 28, 2029aprocitentan · Idorsia Pharmaceuticals · phase 3 · NCT07635914
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.